Male Osteoporosis: A Review

Overview

Journal World J Orthop

Publisher Baishideng Publishing Group

Specialty Orthopedics

Date 2013 Jan 31

PMID 23362466

Citations 20

Authors

Antonio Herrera

Antonio Lobo-Escolar

Jesus Mateo

Jorge Gil

Elena Ibarz

Luis Gracia

Affiliations

Soon will be listed here.

Abstract

Osteoporosis in men is a heterogeneous disease that has received little attention. However, one third of worldwide hip fractures occur in the male population. This problem is more prevalent in people over 70 years of age. The etiology can be idiopathic or secondary to hypogonadism, vitamin D deficiency and inadequate calcium intake, hormonal treatments for prostate cancer, use of toxic and every disease or drug use that alters bone metabolism.Risk factors such as a previous history of fragility fracture should be assessed for the diagnosis. However, risk factors in men are very heterogeneous. There are significant differences in the pharmacological treatment of osteoporosis between men and women fundamentally due to the level of evidence in published trials supporting each treatment. New treatments will offer new therapeutic prospects. The goal of this work is a revision of the present status knowledge about male osteoporosis.

Citing Articles

Treatment for osteoporosis and risk of osteonecrosis of the jaw among female patients in the United Kingdom Clinical Practice Research Datalink.

Persson R, Hagberg K, Pranschke E, Vasilakis-Scaramozza C, Jick S Osteoporos Int. 2024; 36(1):47-60.

PMID: 39400702 DOI: 10.1007/s00198-024-07262-7.

Primary Creep Characterization in Porcine Lumbar Spine Subject to Repeated Loading.

Morino C, Middleton S, Opt Eynde J, Dimbath E, Kait J, Luck J Ann Biomed Eng. 2024; .

PMID: 38951421 DOI: 10.1007/s10439-024-03557-2.

17β-Estradiol (E2) Activates Matrix Mineralization through Genomic/Nongenomic Pathways in MC3T3-E1 Cells.

Suzuki H, Fujiwara Y, Ariyani W, Amano I, Ishii S, Ninomiya A Int J Mol Sci. 2024; 25(9).

PMID: 38731947 PMC: 11083456. DOI: 10.3390/ijms25094727.

A Randomized Clinical Trial of Transgender Women Switching to B/F/TAF: The (mo)BETTA Trial.

Lake J, Hyatt A, Feng H, Debroy P, Kettelhut A, Miao H Open Forum Infect Dis. 2023; 10(4):ofad178.

PMID: 37096146 PMC: 10122488. DOI: 10.1093/ofid/ofad178.

Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians.

Qaseem A, Hicks L, Etxeandia-Ikobaltzeta I, Shamliyan T, Cooney T, Cross Jr J Ann Intern Med. 2023; 176(2):224-238.

PMID: 36592456 PMC: 10885682. DOI: 10.7326/M22-1034.

References

Seeman E . The growth and age-related origins of bone fragility in men. Calcif Tissue Int. 2004; 75(2):100-9. DOI: 10.1007/s00223-004-0289-4. View

Boonen S, Orwoll E, Wenderoth D, Stoner K, Eusebio R, Delmas P . Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res. 2008; 24(4):719-25. DOI: 10.1359/jbmr.081214. View

Sambrook P, Roux C, Devogelaer J, Saag K, Lau C, Reginster J . Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. Bone. 2011; 50(1):289-95. DOI: 10.1016/j.bone.2011.10.024. View

Melton 3rd L, Atkinson E, OConnor M, OFallon W, Riggs B . Bone density and fracture risk in men. J Bone Miner Res. 1998; 13(12):1915-23. DOI: 10.1359/jbmr.1998.13.12.1915. View

Moayyeri A, Kaptoge S, Dalzell N, Bingham S, Luben R, Wareham N . Is QUS or DXA better for predicting the 10-year absolute risk of fracture?. J Bone Miner Res. 2009; 24(7):1319-25. DOI: 10.1359/jbmr.090212. View

Kaufman J, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky G . Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int. 2004; 16(5):510-6. DOI: 10.1007/s00198-004-1713-3. View

Drake M, Murad M, Mauck K, Lane M, Undavalli C, Elraiyah T . Clinical review. Risk factors for low bone mass-related fractures in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2012; 97(6):1861-70. DOI: 10.1210/jc.2011-3058. View

Shimizu Y, Sakai A, Menuki K, Mori T, Isse T, Oyama T . Reduced bone formation in alcohol-induced osteopenia is associated with elevated p21 expression in bone marrow cells in aldehyde dehydrogenase 2-disrupted mice. Bone. 2011; 48(5):1075-86. DOI: 10.1016/j.bone.2011.01.008. View

Smith M, Eastham J, Gleason D, Shasha D, Tchekmedyian S, Zinner N . Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003; 169(6):2008-12. DOI: 10.1097/01.ju.0000063820.94994.95. View

10.

Bessho M, Ohnishi I, Matsumoto T, Ohashi S, Matsuyama J, Tobita K . Prediction of proximal femur strength using a CT-based nonlinear finite element method: differences in predicted fracture load and site with changing load and boundary conditions. Bone. 2009; 45(2):226-31. DOI: 10.1016/j.bone.2009.04.241. View

11.

Schuit S, van der Klift M, Weel A, de Laet C, Burger H, Seeman E . Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone. 2004; 34(1):195-202. DOI: 10.1016/j.bone.2003.10.001. View

12.

Tinetti M, Kumar C . The patient who falls: "It's always a trade-off". JAMA. 2010; 303(3):258-66. PMC: 3740370. DOI: 10.1001/jama.2009.2024. View

13.

Khosla S . Update in male osteoporosis. J Clin Endocrinol Metab. 2010; 95(1):3-10. PMC: 2805483. DOI: 10.1210/jc.2009-1740. View

14.

Amin S, Felson D . Osteoporosis in men. Rheum Dis Clin North Am. 2001; 27(1):19-47. DOI: 10.1016/s0889-857x(05)70186-1. View

15.

Moinuddin M, Jameson K, Syddall H, Aihie Sayer A, Martin H, Robinson S . Cigarette smoking, birthweight and osteoporosis in adulthood: results from the hertfordshire cohort study. Open Rheumatol J. 2008; 2:33-7. PMC: 2577951. DOI: 10.2174/1874312900802010033. View

16.

Kanis J, Bianchi G, Bilezikian J, Kaufman J, Khosla S, Orwoll E . Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos Int. 2011; 22(11):2789-98. PMC: 3555694. DOI: 10.1007/s00198-011-1632-z. View

17.

Adachi J, Lyles K, Colon-Emeric C, Boonen S, Pieper C, Mautalen C . Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial. Osteoporos Int. 2011; 22(9):2539-49. DOI: 10.1007/s00198-010-1514-9. View

18.

Fortinsky R, Iannuzzi-Sucich M, Baker D, Gottschalk M, King M, Brown C . Fall-risk assessment and management in clinical practice: views from healthcare providers. J Am Geriatr Soc. 2004; 52(9):1522-6. DOI: 10.1111/j.1532-5415.2004.52416.x. View

19.

Keaveny T, Hoffmann P, Singh M, Palermo L, Bilezikian J, Greenspan S . Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res. 2008; 23(12):1974-82. PMC: 2686921. DOI: 10.1359/jbmr.080805. View

20.

van der Wielen R, Lowik M, van den Berg H, de Groot L, Haller J, Moreiras O . Serum vitamin D concentrations among elderly people in Europe. Lancet. 1995; 346(8969):207-10. DOI: 10.1016/s0140-6736(95)91266-5. View